New pill could ease psoriatic arthritis pain in 12 weeks

NCT ID NCT07315061

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called D-2570 in 222 adults with active psoriatic arthritis. Participants take the drug or a placebo daily for 12 weeks. The main goal is to see if D-2570 reduces joint tenderness and swelling by at least 20% compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

D-2570

What this could lead to

If successful, D-2570 could offer a new oral treatment option to reduce joint pain and swelling in people with active psoriatic arthritis.

What could go wrong

This is an early Phase 2 trial with a small number of participants. The drug may not work better than placebo, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSA (PSORIATIC ARTHRITIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pleomorphic adenoma psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China School of Medicine

    RECRUITING

    Chengdu, Sichuan, 610041, China